Invivyd Inc

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Invivyd Inc advances VYD222 for COVID-19, faces regulatory challenges

Invivyd Inc's progress with VYD222 for COVID-19 prevention is promising, supported by FDA clearance and financial stability.
While facing challenges in Phase III preparation and regulatory compliance, the company's strengths in neutralizing activity and biomarker research are notable.
Opportunities lie in market growth, regulatory pathways, and enhancing biomarker expectations for VYD222's success.

Invivyd reports robust Q2 earnings, poised for COVID-19 solution success

Invivyd Inc (IVVD) showcased a strong financial performance and promising progress in commercializing VYD222 during the Q2 2023 earnings call.
While facing challenges such as trial complexities and competitive landscape, the company's strengths in financial stability, positive trial results, and experienced management team position it well for future growth.
Opportunities abound in addressing the urgent need for COVID-19 protection, exploring commercial avenues, and establishing a strong market presence with VYD222.

Invivyd Inc reports robust Q3 performance and prepares for VYD222 launch

Invivyd Inc's Q3 2023 earnings call highlighted strong financial performance, progress in the CANOPY trial for VYD222, and strategic preparations for a potential market launch in 2024.
The company's focus on addressing the urgent need for monoclonal antibodies for immunocompromised individuals aligns with significant market opportunities and positions them for future success.
While facing challenges such as regulatory submissions and competitive pressures, Invivyd Inc remains optimistic about the potential impact of VYD222 and expresses gratitude for investor support.

Invivyd Inc reports strong cash position and FDA collaborations

Invivyd Inc focuses on addressing COVID-19 challenges with high efficacy antibodies.
The company's financials show strong cash position and potential for revenue growth.
Opportunities lie in FDA collaborations, clinical trials, and expanding treatment options.
Challenges include the need for revenue generation and uncertainties in product launch.

Invivyd reports solid Q3 earnings, aims for profitability amid FDA challenges

Invivyd Inc's Q3 2024 earnings call showcased strong commercial performance with $9.3 million in PEMGARDA net product revenue. The company faces challenges with FDA warnings but aims for profitability by June 2025. Opportunities in scaling COVID-19 protection and developing potent antibodies position Invivyd for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--( BUSINESS WIRE )--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ: IVVD, ADGI) between November 29, 2021 and December 14, 2021, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2023.

NATIONALLY RANKED ROSEN LAW FIRM Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IVVD, ADGI

BENSALEM, Pa.--( BUSINESS WIRE )--Law Offices of Howard G. Smith announces an investigation on behalf of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (“Adagio” or the “Company”) (NASDAQ: IVVD) investors concerning the Company's possible violations of federal securities laws.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) on Behalf of Investors

SAN DIEGO--( BUSINESS WIRE )--The Class: Robbins LLP informs investors that a shareholder filed a class action on behalf of all purchasers of Invivyd, Inc. (NASDAQ: IVVD) f/k/a Adagio Therapeutics, Inc. common stock between November 29, 2021 and December 14, 2021, for violations of the Securities Exchange Act of 1934. Invivyd, Inc. is a clinical-stage biopharmaceutical company that during the class period was focused on developing a monoclonal antibody (“mAb”) therapy for the prevention and treatment of COVID-19. The Company formed in June 2020, during some of the worst days of the pandemic, to develop drugs for the treatment and prevention of COVID-19 and future coronavirus outbreaks.

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Invivyd, Inc. (IVVD) f/k/a Adagio Therapeutics, Inc.

LOS ANGELES--( BUSINESS WIRE )--The Law Offices of Frank R. Cruz announces an investigation of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (“Adagio” or the “Company”) (NASDAQ: IVVD) on behalf of investors concerning the Company's possible violations of federal securities laws.

The Law Offices of Frank R. Cruz Announces Investigation of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) on Behalf of Investors

Atlanta, Georgia--(Newsfile Corp. - February 1, 2023) - Holzer & Holzer, LLC informs investors that a class action lawsuit has been filed against Invivyd, Inc. ("Invivyd" or the "Company") f/k/a Adagio Therapeutics, Inc. (NASDAQ: IVVD).

SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Invivyd, Inc. (IVVD) Investors - Nationally Ranked Investors' Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Adagio Therapeutics

LOS ANGELES, CA / ACCESSWIRE / February 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd" or "the Company") (NASDAQ:IVVD) (NASDAQ:ADGI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 29, 2021 and December 14, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before April 3, 2023.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

SAN DIEGO--( BUSINESS WIRE )-- Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ: IVVD) common stock between November 29, 2021 and December 14, 2021, both dates inclusive (the “Class Period”). Captioned Brill v. Invivyd, Inc., No. 23-cv-10254 (D. Mass.), the Invivyd class action lawsuit charges Invivyd and certain of its top executives with violations of the Securities Exchange Act of 1934.

IVVD INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

The company's shares have climbed along since an FDA announcement earlier this week.

Why Shares of Invivyd Jumped This Week

Invivyd, Inc. (IVVD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Invivyd, Inc. (IVVD) Upgraded to Buy: Here's Why

WALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, was invited to participate in an FDA-EMA workshop on SARS-CoV-2 monoclonal antibodies held on December 15, 2022. Invivyd's chief scientific officer, Laura Walker, Ph.D., alongside Eli Lilly and Company and Regeneron Pharmaceuticals, Inc., presented a joint industry approach for anti-spike monoclonal antibody development to keep pace with SARS-CoV-2 variants. The meeting featured presentations by scientists, clinicians, regulators, and industry representatives to discuss alternative strategies to support the expedited availability of novel monoclonal antibody therapies including those based on development stage products that have reported positive safety and efficacy data in clinical trials.

Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop

WALTHAM, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Jeremy Gowler as chief operating and commercial officer, effective December 16, 2022, and the promotion of Pete Schmidt, M.D. to chief medical officer, effective immediately.

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

-Broad partnership will strengthen Invivyd's development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies for COVID-19 and beyond-

Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19

Invivyd, Inc. (NASDAQ:IVVD ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Kyra Faircloth - VP, Government Affairs, Advocacy and Corporate Communication David Hering - CEO Laura Walker - Chief Scientific Officer Fred Driscoll - Interim Chief Financial Officer Conference Call Participants PJ Solit - Potomac Capital Management Dana Buska - Feltl Advisors Operator Welcome to the Invivyd Third Quarter 2022 Update Call. I will now turn the call over to Kyra Faircloth, Vice President of Government Affairs, Advocacy and Corporate Communication.

Invivyd, Inc. (IVVD) CEO David Hering on Q3 2022 Results - Earnings Call Transcript

Novel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023

Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David Hering, chief executive officer of Invivyd, is scheduled to participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 4:25 p.m. GMT.

Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference

WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced that it will host a conference call on Thursday, November 10, 2022, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2022, and recent business highlights.

Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights

WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Christine Lindenboom, senior vice president investor relations & corporate communications at Alnylam Pharmaceuticals, Inc., to its board of directors. In addition, Redonda Miller, M.D., M.B.A., president of The Johns Hopkins Hospital, has stepped down from her position on the board.

Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors

WALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Fred Driscoll as interim CFO as well as headcount changes to align resources to its key programs. The changes are designed to improve capital efficiency by reallocating resources to programs and functions to support our key activities on an accelerated timeline. As part of the resource realignment, the company is building out additional discovery and early development positions and has eliminated several corporate and commercial positions, among others, to execute efficiently on the company's corporate strategy, maximize the potential of Invivyd's integrated discovery platform, and advance its pipeline programs, including NVD200 for the prevention and treatment of COVID-19.

Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform

WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases announced today that it will have four poster presentations at ID Week 2022. The posters will share findings from several studies surrounding adintrevimab, including data from the Phase 1 and Phase 2/3 clinical trials.

Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022

NEW YORK, NY / ACCESSWIRE / October 3, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new audio interview with Invivyd. Toni had the pleasure of recently conducting the Interview with David Hering, Chief Executive Officer of Invivyd Inc. (NASDAQ:IVVD).

News for Invivyd Inc Stock (IVVD)